Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Long-term Safety Study of CRISPR CAR T Cell Therapy for Patients with Blood and Solid Cancers

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the long-term safety of a treatment for people with certain types of cancer, specifically hematologic malignancies and solid malignancies. The treatment being studied involves a special type of cell therapy called CRISPR CAR cellular therapy. This therapy uses advanced genetic techniques to modify immune cells, known as CAR T cells, to help them target and fight cancer cells more effectively.

The purpose of this study is to monitor the safety of this treatment over an extended period. Participants in the study have already received the CRISPR CAR cellular therapy. The study will track any side effects or adverse events that may occur, including serious ones, to ensure the treatment is safe for long-term use. Additionally, the study will look at how long participants survive and how long they remain in remission, which means the cancer is not active or growing.

Throughout the study, participants will be regularly monitored by healthcare professionals. This will involve routine check-ups and assessments to gather information about their health and any changes they experience. The study aims to provide valuable insights into the long-term effects of CRISPR CAR cellular therapy, contributing to the understanding and development of new cancer treatments.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant must have already received CRISPR CAR cellular therapy. This therapy involves the use of genetically modified cells to target specific cancer cells.

    The participant must be able to understand and comply with the study procedures and sign a consent form.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to evaluate the participant's current health status. This includes reviewing medical history and any previous treatments received.

    The assessment aims to ensure the participant meets all necessary criteria for the study.

  3. Step 3

    Treatment monitoring

    Participants will be monitored for any adverse events related to the CRISPR CAR cellular therapy. This includes any unexpected medical issues that may arise.

    Monitoring will focus on both serious adverse events and those of special interest, ensuring participant safety throughout the study.

  4. Step 4

    Long-term follow-up

    The study involves a long-term follow-up to assess the overall survival and duration of remission or response to the therapy.

    Participants will be regularly evaluated to track their health status and any changes over time.

  5. Step 5

    Study completion

    The study is estimated to conclude by August 31, 2039. Participants will continue to be monitored until the end of the study period.

    Final assessments will be conducted to gather comprehensive data on the long-term effects of the therapy.

Who can join the trial?

5 criteria

  • The patient must be able to understand and follow the study procedures and must agree to participate by signing a consent form.
  • The patient must have already received **CRISPR CAR cellular therapy**. This is a type of treatment that uses a special technology to modify cells to help fight cancer.
  • The study is open to both male and female patients.
  • The study includes patients with **hematologic malignancy** (cancers that start in blood-forming tissue) or **solid malignancy** (cancers that form in solid organs or tissues).
  • The study is not specifically for vulnerable populations, meaning it does not focus on groups that might need special protection.

Who cannot join the trial?

3 criteria

  • Patients with certain types of cancer, such as hematologic malignancy (cancers that start in blood-forming tissue) or solid malignancy (cancers that form solid tumors), may not be eligible.
  • Individuals who are not within the specified age range for the study may be excluded. The study is open to certain age groups only.
  • Participants who are part of a vulnerable population, which means they might need special protection or care, are not included in this study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

CRISPR CAR Cellular Therapy is a type of treatment that uses a patient's own immune cells, which are modified in the laboratory using CRISPR technology. This modification helps the immune cells better recognize and attack cancer cells. The therapy is designed to treat various types of blood cancers and solid tumors by enhancing the body's natural ability to fight cancer.

What is already known about the treatment

CRISPR CAR Cellular Therapy – This treatment is administered through an infusion, where modified cells are introduced into the patient's bloodstream. Currently, it is being studied in clinical trials to assess its long-term safety and effectiveness in treating various types of cancer, including blood and solid tumors. The main therapeutic use of this therapy is to target and destroy cancer cells. At the molecular level, it works by using CRISPR technology to edit genes in T-cells, equipping them with a chimeric antigen receptor (CAR) that helps them recognize and attack cancer cells. This therapy falls under the pharmacological classification of gene and cell therapies.

Investigated diseases

  • Hematologic Malignancy

    This term refers to cancers that begin in the blood-forming tissue, such as the bone marrow, or in the cells of the immune system. These malignancies can lead to the production of abnormal blood cells, which can interfere with normal blood functions. As the disease progresses, it may cause symptoms like fatigue, frequent infections, and easy bruising or bleeding. Hematologic malignancies include various types such as leukemia, lymphoma, and myeloma. The progression can vary significantly depending on the specific type and subtype of the malignancy.

  • Solid Malignancy

    This term encompasses a group of cancers that form solid tumors in organs or tissues, excluding blood-related cancers. These tumors can occur in various parts of the body, such as the breast, lung, prostate, or colon. As solid malignancies grow, they may invade nearby tissues and organs, potentially causing symptoms related to the affected area. The progression of solid malignancies can vary widely, with some growing slowly and others more aggressively. The growth and spread of these tumors can lead to physical changes and discomfort in the affected region.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-512479-11-00Protocol codeCRSP-ONC-LTFEstimated enrolment70 patientsSponsorCRISPR Therapeutics AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).